Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX) today and set a price target of $62. The company’s shares closed yesterday at $56.90.
Rivkind Koffler wrote:
“We Expect Weakness on Failed Fulvestrant Study Rating Neutral Previous Rating No Change Price (10/29) $56.90 Price Target $62.00 Previous Price Target No Change.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 8.7% and a 43.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Supernus Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Eagle Pharmaceuticals Inc is a Strong Buy with an average price target of $78.50.
See today’s analyst top recommended stocks >>
Eagle Pharmaceuticals Inc’s market cap is currently $856M and has a P/E ratio of 29.95. The company has a Price to Book ratio of 4.61.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
